Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
Use of hypnotics is often associated with next‐morning residual effects and a higher risk of motor vehicle accidents. Measuring next‐morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driving performance following administration of daridorexant, a n...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics Jg. 111; H. 6; S. 1334 - 1342 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.06.2022
|
| Schlagworte: | |
| ISSN: | 0009-9236, 1532-6535, 1532-6535 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Use of hypnotics is often associated with next‐morning residual effects and a higher risk of motor vehicle accidents. Measuring next‐morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia. Sixty healthy male and female subjects (50–79 years of age) were randomized in a placebo‐ and active‐controlled, four‐way cross‐over study. Each subject received evening administration of daridorexant 50 and 100 mg, zopiclone 7.5 mg, and placebo, in separate treatment phases of 4 days. Simulated driving performance was assessed after initial (day 2) and repeated dosing (day 5), 9 hours postdose. Standard deviation of the lateral position (SDLP) was the main outcome. On both days, with zopiclone, SDLP increased significantly compared with placebo, which confirmed sensitivity of the simulator. With daridorexant, on day 2, the placebo‐corrected mean (97.5% confidence interval) SDLP increased by 2.19 cm (0.46–3.93) and 4.43 cm (2.72–6.15) for 50 and 100 mg, respectively. On day 5, SDLP values for both daridorexant doses were significantly below the prespecified threshold of impairment (2.6 cm) and statistically not different from placebo. Daridorexant showed a lower self‐rated driving quality and higher effort compared to placebo on day 2 but not on day 5. In non‐insomnia subjects, daridorexant impaired simulated driving after initial but not after repeated dosing. Subjects should be cautioned about driving until they know how daridorexant affects them. |
|---|---|
| AbstractList | Use of hypnotics is often associated with next-morning residual effects and a higher risk of motor vehicle accidents. Measuring next-morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia. Sixty healthy male and female subjects (50-79 years of age) were randomized in a placebo- and active-controlled, four-way cross-over study. Each subject received evening administration of daridorexant 50 and 100 mg, zopiclone 7.5 mg, and placebo, in separate treatment phases of 4 days. Simulated driving performance was assessed after initial (day 2) and repeated dosing (day 5), 9 hours postdose. Standard deviation of the lateral position (SDLP) was the main outcome. On both days, with zopiclone, SDLP increased significantly compared with placebo, which confirmed sensitivity of the simulator. With daridorexant, on day 2, the placebo-corrected mean (97.5% confidence interval) SDLP increased by 2.19 cm (0.46-3.93) and 4.43 cm (2.72-6.15) for 50 and 100 mg, respectively. On day 5, SDLP values for both daridorexant doses were significantly below the prespecified threshold of impairment (2.6 cm) and statistically not different from placebo. Daridorexant showed a lower self-rated driving quality and higher effort compared to placebo on day 2 but not on day 5. In non-insomnia subjects, daridorexant impaired simulated driving after initial but not after repeated dosing. Subjects should be cautioned about driving until they know how daridorexant affects them. Use of hypnotics is often associated with next-morning residual effects and a higher risk of motor vehicle accidents. Measuring next-morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia. Sixty healthy male and female subjects (50-79 years of age) were randomized in a placebo- and active-controlled, four-way cross-over study. Each subject received evening administration of daridorexant 50 and 100 mg, zopiclone 7.5 mg, and placebo, in separate treatment phases of 4 days. Simulated driving performance was assessed after initial (day 2) and repeated dosing (day 5), 9 hours postdose. Standard deviation of the lateral position (SDLP) was the main outcome. On both days, with zopiclone, SDLP increased significantly compared with placebo, which confirmed sensitivity of the simulator. With daridorexant, on day 2, the placebo-corrected mean (97.5% confidence interval) SDLP increased by 2.19 cm (0.46-3.93) and 4.43 cm (2.72-6.15) for 50 and 100 mg, respectively. On day 5, SDLP values for both daridorexant doses were significantly below the prespecified threshold of impairment (2.6 cm) and statistically not different from placebo. Daridorexant showed a lower self-rated driving quality and higher effort compared to placebo on day 2 but not on day 5. In non-insomnia subjects, daridorexant impaired simulated driving after initial but not after repeated dosing. Subjects should be cautioned about driving until they know how daridorexant affects them.Use of hypnotics is often associated with next-morning residual effects and a higher risk of motor vehicle accidents. Measuring next-morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia. Sixty healthy male and female subjects (50-79 years of age) were randomized in a placebo- and active-controlled, four-way cross-over study. Each subject received evening administration of daridorexant 50 and 100 mg, zopiclone 7.5 mg, and placebo, in separate treatment phases of 4 days. Simulated driving performance was assessed after initial (day 2) and repeated dosing (day 5), 9 hours postdose. Standard deviation of the lateral position (SDLP) was the main outcome. On both days, with zopiclone, SDLP increased significantly compared with placebo, which confirmed sensitivity of the simulator. With daridorexant, on day 2, the placebo-corrected mean (97.5% confidence interval) SDLP increased by 2.19 cm (0.46-3.93) and 4.43 cm (2.72-6.15) for 50 and 100 mg, respectively. On day 5, SDLP values for both daridorexant doses were significantly below the prespecified threshold of impairment (2.6 cm) and statistically not different from placebo. Daridorexant showed a lower self-rated driving quality and higher effort compared to placebo on day 2 but not on day 5. In non-insomnia subjects, daridorexant impaired simulated driving after initial but not after repeated dosing. Subjects should be cautioned about driving until they know how daridorexant affects them. |
| Author | Brooks, Sander Zuiker, Rob G. Muehlan, Clemens Dingemanse, Jasper Jacobs, Gabriël E. Vaillant, Cedric Meinel, Michael |
| Author_xml | – sequence: 1 givenname: Clemens surname: Muehlan fullname: Muehlan, Clemens email: clemens.muehlan@idorsia.com organization: Idorsia Pharmaceuticals Ltd – sequence: 2 givenname: Sander surname: Brooks fullname: Brooks, Sander organization: Erasmus University Medical Center – sequence: 3 givenname: Cedric surname: Vaillant fullname: Vaillant, Cedric organization: Idorsia Pharmaceuticals Ltd – sequence: 4 givenname: Michael surname: Meinel fullname: Meinel, Michael organization: Idorsia Pharmaceuticals Ltd – sequence: 5 givenname: Gabriël E. surname: Jacobs fullname: Jacobs, Gabriël E. organization: Leiden University Medical Center – sequence: 6 givenname: Rob G. surname: Zuiker fullname: Zuiker, Rob G. organization: Centre for Human Drug Research – sequence: 7 givenname: Jasper surname: Dingemanse fullname: Dingemanse, Jasper organization: Idorsia Pharmaceuticals Ltd |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35426136$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kEtLAzEUhYMo2lbBXyBZunBqHjPpZFlbX1Cw0LoeMsmNRGYyNUl9_HuntAoXDpfzcRbfEB37zgNCl5SMKSHsVm_SmBWSHaEBLTjLRMGLYzQghMhMMi7O0DDG9_7NZVmeojNe5ExQLgZIz4P7dP4NLyHYLrTKa8DKJgj4DkxyLeCpaZ13MQWVXOdxZ_FcBWe6AN_Kpxs8jRH6M9h5rPAKfHTJfQJeuXbbqNSFc3RiVRPh4pAj9Ppwv549ZYuXx-fZdJHpnBKW1bXQ1BItNZVUlKym1lAliKhrbrkoc2YmQCc5J1bm2oDQRIi8lrw0k1ppy0foer-7Cd3HFmKqWhc1NI3y0G1jxURBheR5yXv06oBu6xZMtQmuVeGn-hPTA9ke-HIN_Pz3lFQ74VUvvNoJr2bL9S75L_MNdOo |
| CitedBy_id | crossref_primary_10_3390_molecules27186041 crossref_primary_10_1002_npr2_12436 crossref_primary_10_1111_bcpt_13930 crossref_primary_10_1111_jsr_13902 crossref_primary_10_1177_10600280221143794 crossref_primary_10_3390_ijms26178700 crossref_primary_10_1177_87551225221112546 crossref_primary_10_12793_tcp_2024_32_e5 crossref_primary_10_1007_s40263_022_00980_8 crossref_primary_10_1016_j_rcsop_2024_100538 crossref_primary_10_1080_14740338_2023_2243217 crossref_primary_10_1111_pcn_13888 crossref_primary_10_1093_jat_bkaf032 crossref_primary_10_1016_j_jpet_2025_103624 crossref_primary_10_1002_hup_70007 crossref_primary_10_1016_j_euroneuro_2024_01_011 crossref_primary_10_1093_schizbullopen_sgae025 crossref_primary_10_52965_001c_37400 crossref_primary_10_1371_journal_pone_0332366 crossref_primary_10_1002_prp2_1183 crossref_primary_10_1111_cts_70282 crossref_primary_10_1007_s40263_023_00987_9 |
| ContentType | Journal Article |
| Copyright | 2022 Idorsia Pharmaceuticals Ltd. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. 2022 Idorsia Pharmaceuticals Ltd. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| Copyright_xml | – notice: 2022 Idorsia Pharmaceuticals Ltd. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. – notice: 2022 Idorsia Pharmaceuticals Ltd. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| DBID | 24P CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/cpt.2592 |
| DatabaseName | Wiley Online Library Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1532-6535 |
| EndPage | 1342 |
| ExternalDocumentID | 35426136 CPT2592 |
| Genre | article Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Idorsia Pharmaceuticals Ltd |
| GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 24P 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAYOK AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AHBTC AI. AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG COF CS3 DCZOG DPXWK DU5 EBS EE. EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR WYJ X7M Y6R YCJ YFH YOC YXB ZGI ZXP ZZTAW AAMMB AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c4102-bb6c1f0c9c191682b1fd1a606bb3f36842d7e17430f94cde6c0664b938d7bacf3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000789547100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0009-9236 1532-6535 |
| IngestDate | Tue Aug 05 10:16:02 EDT 2025 Mon Jul 21 06:00:38 EDT 2025 Wed Jan 22 16:26:17 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2022 Idorsia Pharmaceuticals Ltd. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4102-bb6c1f0c9c191682b1fd1a606bb3f36842d7e17430f94cde6c0664b938d7bacf3 |
| Notes | These authors contributed equally to the manuscript. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.2592 |
| PMID | 35426136 |
| PQID | 2651693483 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2651693483 pubmed_primary_35426136 wiley_primary_10_1002_cpt_2592_CPT2592 |
| PublicationCentury | 2000 |
| PublicationDate | June 2022 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical pharmacology and therapeutics |
| PublicationTitleAlternate | Clin Pharmacol Ther |
| PublicationYear | 2022 |
| References | 2015; 6 2015; 38 2010; 14 2021; 44 2020; 42 2011 1997; 21 2019; 33 2019; 34 2018; 104 2008; 9 2009 2022; 21 2011; 4 2011; 6 1993; 3 2012; 31 2019; 60 2013; 17 2010; 24 2022 1982; 217 2020; 94 2013; 53 2018; 235 2007; 8 2016; 233 2018 2013; 60 2014; 36 2017 2019; 29 1984; 18 2011; 26 2020; 87 2007; 22 2012; 219 |
| References_xml | – year: 2011 – year: 2009 – volume: 4 start-page: 359 year: 2011 end-page: 371 article-title: Standard operation procedures for conducting the on‐the‐road driving test, and measurement of the standard deviation of lateral position (SDLP) publication-title: Int. J. Gen. Med. – volume: 219 start-page: 775 year: 2012 end-page: 781 article-title: Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality publication-title: Psychopharmacology – volume: 60 start-page: 64 year: 2019 end-page: 69 article-title: Predictors of simulated driving performance in Huntington’s disease publication-title: Park. Relat. Disord. – volume: 29 start-page: 847 year: 2019 end-page: 857 article-title: Multiple‐dose clinical pharmacology of ACT‐541468, a novel dual orexin receptor antagonist, following repeated‐dose morning and evening administration publication-title: Eur. Neuropsychopharmacol. – volume: 44 start-page: A136 issue: Suppl. 2 year: 2021 article-title: Acute effects of seltorexant, a selective orexin‐2 antagonist (JNJ‐ 42847922), on driving after bedtime administration publication-title: Sleep – volume: 53 start-page: 9 year: 2013 end-page: 16 article-title: Comparison of driving simulator performance with real driving after alcohol intake: a randomised, single blind, placebo‐controlled, cross‐over trial publication-title: Accid. Anal. Prev. – volume: 33 start-page: 791 year: 2019 end-page: 800 article-title: Evaluation of simulated driving in comparison to laboratory‐based tests to assess the pharmacodynamics of alprazolam and alcohol publication-title: J. Psychopharmacol. – volume: 6 start-page: 86 year: 2015 end-page: 97 article-title: A randomized, crossover, placebo‐controlled clinical trial to assess the sensitivity of the CRCDS Mini‐Sim to the next‐day residual effects of zopiclone publication-title: Ther. Adv. Drug Saf. – volume: 34 start-page: 326 year: 2019 end-page: 335 article-title: Clinical pharmacology of the dual orexin receptor antagonist ACT‐541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single‐dose morning and repeated‐dose evening administration publication-title: J. Psychopharmacol. – volume: 217 start-page: 79 year: 1982 end-page: 81 article-title: Diazepam impairs lateral position control in highway driving publication-title: Science – volume: 14 start-page: 19 year: 2010 end-page: 31 article-title: The hyperarousal model of insomnia: a review of the concept and its evidence publication-title: Sleep Med. Rev. – volume: 87 start-page: 347 year: 2020 end-page: 356 article-title: Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder publication-title: Ann. Neurol. – year: 2018 – volume: 42 start-page: 1 year: 2020 end-page: 9 article-title: On‐the‐road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers publication-title: Sleep – volume: 24 start-page: 1619 year: 2010 end-page: 1629 article-title: Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects publication-title: J. Psychopharmacol. – volume: 94 start-page: 22 year: 2020 end-page: 32 article-title: Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder publication-title: Neurology – volume: 235 start-page: 1283 year: 2018 end-page: 1294 article-title: Comparing the effects of oxazepam and diazepam in actual highway driving and neurocognitive test performance: a validation study publication-title: Psychopharmacology – volume: 26 start-page: 434 year: 2011 end-page: 439 article-title: Effects of alcohol on highway driving in the STISIM driving simulator publication-title: Hum. Psychopharmacol. – volume: 21 start-page: 161 year: 1997 end-page: 168 article-title: Is behavioral tolerance learned? publication-title: Alcohol Health Res. World – volume: 22 start-page: 1335 year: 2007 end-page: 1350 article-title: The efficacy and safety of drug treatments for chronic insomnia in adults: a meta‐analysis of RCTs publication-title: J. Gen. Intern. Med. – volume: 17 start-page: 153 year: 2013 end-page: 159 article-title: Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment publication-title: Sleep Med. Rev. – volume: 6 start-page: 209 year: 2011 end-page: 218 article-title: Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability publication-title: Curr. Drug. Saf. – volume: 31 start-page: 3178 year: 2012 end-page: 3191 article-title: A maximally selected test of symmetry about zero publication-title: Statist. Med. – volume: 18 start-page: 121 year: 1984 end-page: 129 article-title: Driving performance under the influence of drugs: rationale for, and application of, a new test publication-title: Br. J. Clin. Pharmacol. – volume: 9 start-page: 404 year: 2008 end-page: 413 article-title: The impact of benzodiazepines on safe driving publication-title: Traffic Inj. Prev. – volume: 38 start-page: 1803 year: 2015 end-page: 1813 article-title: On‐the‐road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non‐elderly healthy volunteers publication-title: Sleep – year: 2022 – volume: 60 start-page: 31 year: 2013 end-page: 34 article-title: Lorazepam impairs highway driving performance more than heavy alcohol consumption publication-title: Accid. Anal. Prev. – volume: 3 start-page: 441 year: 1993 end-page: 459 article-title: Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic publication-title: Drugs Aging – volume: 233 start-page: 3341 year: 2016 end-page: 3351 article-title: On‐the‐road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly publication-title: Psychopharmacology – volume: 21 start-page: 125 year: 2022 end-page: 139 article-title: Sleep and daytime effects of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double‐blind, 3‐month, placebo‐controlled, phase 3 trials publication-title: Lancet Neurol. – year: 2017 – volume: 34 year: 2019 article-title: Driving performance and neurocognitive skills of long‐term users of benzodiazepine anxiolytics and hypnotics publication-title: Hum. Psychopharmacol. – volume: 8 start-page: 171 year: 2007 end-page: 181 article-title: The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness publication-title: Nat. Rev. Neurosci. – volume: 104 start-page: 1022 year: 2018 end-page: 1029 article-title: Accelerated development of the dual orexin receptor antagonist ACT‐541468: integration of a microtracer in a first‐in‐human study publication-title: Clin. Pharmacol. Ther. – volume: 36 start-page: 141 year: 2014 end-page: 150 article-title: Zopiclone’s residual effects on actual driving performance in a standardized test: a pooled analysis of age and sex effects in 4 placebo‐controlled studies publication-title: Clin. Ther. |
| SSID | ssj0004988 |
| Score | 2.50404 |
| Snippet | Use of hypnotics is often associated with next‐morning residual effects and a higher risk of motor vehicle accidents. Measuring next‐morning effects on driving... Use of hypnotics is often associated with next-morning residual effects and a higher risk of motor vehicle accidents. Measuring next-morning effects on driving... |
| SourceID | proquest pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1334 |
| SubjectTerms | Automobile Driving Cross-Over Studies Double-Blind Method Female Humans Imidazoles Male Orexin Receptor Antagonists - adverse effects Psychomotor Performance Pyrrolidines |
| Title | Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.2592 https://www.ncbi.nlm.nih.gov/pubmed/35426136 https://www.proquest.com/docview/2651693483 |
| Volume | 111 |
| WOSCitedRecordID | wos000789547100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF6kevDi-1FfrCA9NTTJbnc3R20tHrQEWqG3kH1BDqYlbcX-e3eS1lDwIHjZHJJAYGYn3-zMfB9CDzKlfpoK4zHT5R61xnqRFQy6CLu-JpRYXaqWvPLhUEwmUbzuqoRZmIof4ufADXZGGa9hg6dy3qlJQ9UMBK4jF353g4Bw8OiQxvVMZCTERkXNgRi2IZ71w87mzd9A5TZGLX8yg8P_fN4ROlhDS_xY-cIx2jH5CWrFFTf1qo3H9ajVvI1bOK5Zq1enSPWLDA4XcFyPEuBSQRw_GQ0S9HibaBdPLe67TBukSr6cfdq4KiAbjbMcp3gErfEQTPEo-wCRsGlxht4Hz-Pei7dWYPAUdcjDk5KpwPoqUi6tYyKUgdVB6nIeKYklUMLT3EBO49uIKm2YcgiGyogIzWWqLDlHjXyam0uEHQ4yzOdcacupAWRHqKHWMqaoJpY30f3GGInzcChbpLmZLudJyKCWR6ggTXRRWSmZVVQcCelCCkhYE7VKY_zcqNiYw8SZIQEzJL14DNervz54jfZDmHQoD1xuUGNRLM0t2lOfi2xe3JW-5lY-EW4dxm_fRhbasA |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Ja8JAFH5IW2gv3Re7TqF4Mhgz4yShp1YrlloJaMFbSGYBD43iUuq_77zEGIQeCj3lkAwE3syb723fB_AQR8yOIk9ZXDVci2mlLV97HLsIG7akjGqZqpZ03V7PGw79oASP-SxMxg-xTrjhyUj9NR5wTEjXCtZQMUGFa9_4321mLiXs53NYUAxF-p6Xy6gZFMNz5lnbqeUrf0OVmyA1vWXaB__6v0PYX4FL8pTthiMoqeQYKkHGTr2skkExbDWrkgoJCt7q5QmI1nSE6QUSFMMEJNUQJ89Kogg92aTaJWNNWibWRrGSb2OhKslKyEqSUUIi0sfmeHSnpD_6RJmw8fQUPtovg2bHWmkwWIIZ7GHFMRd1bQtfmMCOe05c17IemagnjqmmWMSTrsKoxtY-E1JxYTAMi33qSTeOhKZnsJWME3UBxCAhxW3XFVK7TCG2o0wxrTkXTFLtluE-t0Zo9jgWLqJEjRez0OFYzaPMo2U4z8wUTjIyjpA2MAikvAyV1BrrFxkfsxMaM4RohrAZDPB5-dcP72C3M3jvht3X3tsV7Dk495CmX65haz5dqBvYEV_z0Wx6m268H_PK3KA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB6Kinjx_ajPFaSnBtPsdjfBk1qLYimBVugtJPuAHkxKq2L_vTtJ01DwIHjKIQkE5pFvZna-D-AmiZkbx752uG4LhxltnMD4HE8Rtl1FGTUqVy3piX7fH42CsAZ35S5MwQ-xbLhhZOT5GgNcT5S5rVhD5QQVrgObf9dZW-RR6bGwWooMfL-UUbMohpfMs653W775G6pcBan5X6a786_v24XtBbgk94U37EFNp_vQCAt26nmTDKtlq1mTNEhY8VbPD0B2pmNsL5CwWiYguYY4edAKRejJKtUuyQzp2FobxUq-rYWapBgha0XGKYnJAA_HYzolg_E7yoRl00N46z4NH5-dhQaDI5nFHk6ScNkyrgykLey47yUto1qxrXqShBqKQzwlNFY1rgmYVJpLi2FYElBfiSSWhh7BWpql-gSIRUKau0JIZQTTiO0o08wYziVT1Ig6XJfWiKyP4-AiTnX2OYs8jtM8ynxah-PCTNGkIOOIaBuLQMrr0MitsbxR8DF7kTVDhGaIHsMhXk__-uAVbIadbtR76b-ewZaHaw959-Uc1j6mn_oCNuTXx3g2vcz97gezhNwb |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Driving+Performance+after+Bedtime+Administration+of+Daridorexant%2C+Assessed+in+a+Sensitive+Simulator&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Muehlan%2C+Clemens&rft.au=Brooks%2C+Sander&rft.au=Vaillant%2C+Cedric&rft.au=Meinel%2C+Michael&rft.date=2022-06-01&rft.issn=0009-9236&rft.eissn=1532-6535&rft.volume=111&rft.issue=6&rft.spage=1334&rft.epage=1342&rft_id=info:doi/10.1002%2Fcpt.2592&rft.externalDBID=10.1002%252Fcpt.2592&rft.externalDocID=CPT2592 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9236&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9236&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9236&client=summon |